Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Best

Showing results (81-90 of 142) with videos related to

Pageof 15
Sort By:
Journal of Clinical Periodontology|April 1, 1984
Phenytoin induced gingival overgrowth in institutionalized epilepticsT Hassell, J O'Donnell, J Pearlman, et al.
Journal of Environmental Management|February 4, 2014
A screening-level modeling approach to estimate nitrogen loading and standard exceedance risk, with application to the Tippecanoe River watershed, IndianaGuoxiang Yang, Elly P H Best, Tim Whiteaker, et al.
Rheumatology and Therapy|October 18, 2016
Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional SurveyDana B DiBenedetti, Xiaolei Zhou, Maria Reynolds, et al.
Chemosphere|July 28, 2005
Effects, transfer, and fate of RDX from aged soil in plants and wormsE P H Best, K N Geter, H E Tatem, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 11, 2005
Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphomaJennie H Best, John Hornberger, Stephen J Proctor, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|November 3, 2005
Effect of a metal alloy fuel catalyst on bacterial growthRuma Ghosh, Claudia Koerting, Steven L Suib, et al.
Journal of Medical Economics|July 17, 2012
Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the USYevgeniy Samyshkin, Anne-Laure Guillermin, Jennie H Best, et al.
Clinicoeconomics and Outcomes Research : CEOR|January 11, 2020
Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell ArteritisJennie H Best, Amanda M Kong, David M Smith, et al.
Cardiovascular Diabetology|March 26, 2013
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goalsAlison R Meloni, Mary Beth DeYoung, Jenny Han, et al.
The Annals of Pharmacotherapy|February 6, 2014
Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargineManjiri Pawaskar, Katherine R Tuttle, Qian Li, et al.
Pageof 15

Showing results (81-90 of 142) with videos related to

Sort By:
Pageof 15
Journal of Clinical Periodontology|April 1, 1984
Phenytoin induced gingival overgrowth in institutionalized epilepticsT Hassell, J O'Donnell, J Pearlman, et al.
Journal of Environmental Management|February 4, 2014
A screening-level modeling approach to estimate nitrogen loading and standard exceedance risk, with application to the Tippecanoe River watershed, IndianaGuoxiang Yang, Elly P H Best, Tim Whiteaker, et al.
Rheumatology and Therapy|October 18, 2016
Assessing Methotrexate Adherence in Rheumatoid Arthritis: A Cross-Sectional SurveyDana B DiBenedetti, Xiaolei Zhou, Maria Reynolds, et al.
Chemosphere|July 28, 2005
Effects, transfer, and fate of RDX from aged soil in plants and wormsE P H Best, K N Geter, H E Tatem, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 11, 2005
Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphomaJennie H Best, John Hornberger, Stephen J Proctor, et al.
Langmuir : the ACS Journal of Surfaces and Colloids|November 3, 2005
Effect of a metal alloy fuel catalyst on bacterial growthRuma Ghosh, Claudia Koerting, Steven L Suib, et al.
Journal of Medical Economics|July 17, 2012
Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the USYevgeniy Samyshkin, Anne-Laure Guillermin, Jennie H Best, et al.
Clinicoeconomics and Outcomes Research : CEOR|January 11, 2020
Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell ArteritisJennie H Best, Amanda M Kong, David M Smith, et al.
Cardiovascular Diabetology|March 26, 2013
Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goalsAlison R Meloni, Mary Beth DeYoung, Jenny Han, et al.
The Annals of Pharmacotherapy|February 6, 2014
Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargineManjiri Pawaskar, Katherine R Tuttle, Qian Li, et al.
Pageof 15